Core Insights - Can-Fite BioPharma Ltd. has received a notice of allowance for a Canadian patent on Namodenoson, an A3 adenosine receptor agonist, for its use in reducing fat mass and body weight, positioning it as a potential anti-obesity therapy [1][2] - The global obesity treatment market is projected to reach $60.5 billion by 2030, with a compound annual growth rate (CAGR) of approximately 22%, driven by increasing disease prevalence and demand for effective oral therapies [5] Company Overview - Can-Fite BioPharma is a biotechnology company focused on developing small molecule drugs for oncological and inflammatory diseases, with Namodenoson currently in clinical trials for various conditions including Metabolic Dysfunction-Associated Steatohepatitis (MASH) and advanced liver cancer [3][7] - The company holds patents for Namodenoson in the United States and Australia, and it has demonstrated a strong safety profile in clinical studies [3][6] Clinical Development - Namodenoson has shown efficacy in reducing fat levels by increasing adiponectin hormone and has resulted in a 2.3% weight loss in a Phase IIa study for MASH after three months [4] - The drug is currently undergoing pivotal Phase III trials for advanced liver cancer and Phase IIb trials for MASH, indicating its potential in multiple therapeutic areas [6][7]